GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLM) » Definitions » Common Stock

APLM (Apollomics) Common Stock : $0.01 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Apollomics Common Stock?

Apollomics's quarterly common stock stayed the same from Jun. 2023 ($0.01 Mil) to Dec. 2023 ($0.01 Mil) but then increased from Dec. 2023 ($0.01 Mil) to Jun. 2024 ($0.01 Mil).

Apollomics's annual common stock increased from Dec. 2021 ($0.04 Mil) to Dec. 2022 ($0.04 Mil) but then declined from Dec. 2022 ($0.04 Mil) to Dec. 2023 ($0.01 Mil).

Apollomics Common Stock Historical Data

The historical data trend for Apollomics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Common Stock Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Common Stock
0.04 0.04 0.04 0.01

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial 0.04 0.04 0.01 0.01 0.01

Apollomics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Apollomics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLM) » Definitions » Common Stock
Comparable Companies
MBIO APM CYCN NLSP PRTG PHIO VRAX BIXT ADTX DWTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
APLMW:USA
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Website
https://www.apollomicsinc.com
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.